- Home
- HRMY vs SSL Comparison
HRMY vs SSL Comparison
Compare HRMY & SSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- SSL
- Stock Information
- Founded
- HRMY 2017
- SSL 1950
- Country
- HRMY United States
- SSL South Africa
- Employees
- HRMY N/A
- SSL N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- SSL Oil & Gas Production
- Sector
- HRMY Health Care
- SSL Energy
- Exchange
- HRMY Nasdaq
- SSL Nasdaq
- Market Cap
- HRMY 2.0B
- SSL 2.3B
- IPO Year
- HRMY 2020
- SSL N/A
- Fundamental
- Price
- HRMY $31.89
- SSL $5.21
- Analyst Decision
- HRMY Strong Buy
- SSL
- Analyst Count
- HRMY 9
- SSL 0
- Target Price
- HRMY $54.22
- SSL N/A
- AVG Volume (30 Days)
- HRMY 611.9K
- SSL 1.3M
- Earning Date
- HRMY 08-05-2025
- SSL 01-01-0001
- Dividend Yield
- HRMY N/A
- SSL N/A
- EPS Growth
- HRMY 13.13
- SSL N/A
- EPS
- HRMY 2.62
- SSL N/A
- Revenue
- HRMY $744,852,000.00
- SSL $13,819,021,376.00
- Revenue This Year
- HRMY $20.10
- SSL N/A
- Revenue Next Year
- HRMY $18.01
- SSL $2.76
- P/E Ratio
- HRMY $12.17
- SSL N/A
- Revenue Growth
- HRMY 20.62
- SSL N/A
- 52 Week Low
- HRMY $26.47
- SSL $2.78
- 52 Week High
- HRMY $41.61
- SSL $8.40
- Technical
- Relative Strength Index (RSI)
- HRMY 36.85
- SSL 64.06
- Support Level
- HRMY $32.39
- SSL $5.19
- Resistance Level
- HRMY $33.42
- SSL $5.52
- Average True Range (ATR)
- HRMY 1.06
- SSL 0.13
- MACD
- HRMY -0.47
- SSL 0.03
- Stochastic Oscillator
- HRMY 6.91
- SSL 69.90
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SSL Sasol Ltd.
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main segments: Energy business and Chemical business. It generates maximum revenue from the Chemicals segment. The company operates coal mines and its upstream interests in oil and gas, both of which are used as feedstock in the company's energy and chemicals operations. Sasol markets commodity and performance chemicals, sells liquid fuel products, and markets, distributes and transports pipeline gas. Geographically the company generates the majority of its revenue from South Africa.